SCHEMBL23328985

SCHEMBL23328985

CNC1CCN(c2ccc(C(C)C)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.47
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
MAPK1 P28482 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
ALOX15 P16050 2/20 0.44
ALOX12 P18054 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
HRH4 Q9H3N8 10/20 0.43
LMNA P02545 2/20 0.43
PANK3 Q9H999 3/20 0.42
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3440289 0.84 MAPT (0.55) ALDH1A1MAPTMAPK1SMN1; SMN2L3MBTL1
SCHEMBL785834 0.82 KMT2A (0.50) MAPTMAPK1KDM4EGAA
SCHEMBL20004338 0.80 HRH3 (0.50) HRH3ALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL8728954 0.80 ADRB1 (0.50) ALDH1A1MAPTSMN1; SMN2L3MBTL1KDM4E
SCHEMBL15187981 0.80 HRH3 (0.50) HRH3ALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL10147276 0.80 USP2 (0.54) HRH3ALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL20883550 0.80 RORC (0.51) ALDH1A1MAPTMAPK1SMN1; SMN2L3MBTL1
SCHEMBL20251137 0.79 MAPT (0.51) HRH3ALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL21590255 0.79 NPY5R (0.46) HRH3L3MBTL1HRH4
SCHEMBL22837853 0.79 LTA4H (0.41) ALDH1A1MAPTSMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 HRH3 4083/4885ALDH1A1 748/4885MAPT 3243/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 HRH3 4216/4885ALDH1A1 642/4885MAPT 3081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.